| Sumario: | Background: Gait variability is a sensitive marker of neuromotor function and a clinically relevant indicator of fall risk and mobility impairment in neurological and geriatric populations. The Enhanced Gait Variability Index (eGVI) has emerged as a promising composite measure that captures multidimensional gait irregularity in a single interpretable score, offering a practical advantage over single-parameter approaches. Despite growing clinical interest, the evidence base supporting its standardized implementation has not been mapped. Objectives: To characterize populations and clinical contexts where the eGVI has been applied, map assessment protocol heterogeneity, and identify methodological gaps limiting precision medicine-aligned implementation in neurological and geriatric rehabilitation. Methods: A scoping review following PRISMA-ScR guidelines was conducted using PubMed, CINAHL, Scopus, Emcare, and Web of Science. Peer-reviewed studies reporting eGVI outcomes were included. Data were extracted on participant characteristics, gait assessment protocols, and outcomes, with attention to factors influencing clinical interpretation. Results: Eighteen studies involving 1,915 participants were included, predominantly examining Parkinson's disease (39%) and older adult populations (22%). The eGVI demonstrated preliminary sensitivity to neuromotor impairment, age-related gait changes, and increased task complexity during dual-task walking; findings were most consistent in Parkinson's disease, based on limited number of studies (n = 7). Substantial heterogeneity in walkway systems, walking conditions, assistive device use, and reference populations limited comparability. Conclusion: While the eGVI shows promise as a clinical outcome measure, protocol variability and reliance on a single unvalidated normative reference limit its clinical use. Population-specific protocols and normative data consistent with a precision medicine approach, are essential for reliable adoption.
|
|---|